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A 38-year-old woman withMS receiving natalizumab presented to the neurology clinic with the
complaint of a new neurologic symptom.
Clinical course
The patient had a 6-year history of clinically stable MS, albeit exhibiting radiographic pro-
gression despite strict adherence to daily subcutaneous glatiramer acetate (GA). Furthermore,
on switching first to weekly IM interferon beta (IFN-β)1a, she experienced clinical relapses and
subsequently developed recalcitrant transaminitis while using three times weekly, subcutaneous
IFN-β 1b (figure 1).
Owing to continued disease activity and side effects from GA and IFN, she was switched to
monthly IV natalizumab despite John Cunningham Polyomavirus antibody positivity (JCV
Ab+) with an Ab index 3.37–3.83. She remained clinically and radiographically stable from the
inception of natalizumab with surveillance MRIs performed quarterly. However, after her 47th
natalizumab infusion, she developed a coarse action and position tremor involving her right
distal upper extremity. Brain MRI revealed a nonenhancing left thalamic T2 hyperintensity
(figure 2, A and B).
Natalizumab was suspended while her physicians investigated the underlying etiology for her
new clinical symptom and corresponding imaging abnormality. CSF analyses was non-
inflammatory and JCV DNA was undetectable by PCR. The initial diagnostic supposition was
that the lesion was potentially on the basis of inflammatory demyelination, even in the absence
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of gadolinium (Gd) enhancement. The patient was treated
empirically with 1 g IV methylprednisolone daily for 3 doses
without benefit.
Given concerns of her history of protracted natalizumab
treatment and a high JCV antibody index, monthly serial
MRIs were obtained (figure 2, C–G), which showed lesion
progression, although JCV DNA was not detectable on serial
CSF PCR analyses (4 in total).
Over time, the patient’s tremor gradually worsened despite
treatment with clonazepam and carbamazepine. Botulinum
injection in combination with levetiracetam did mitigate the
amplitude and frequency characteristics of the tremor such
that the patient was able to recognize functional improve-
ments. Notwithstanding such benefits on her tremor, she later
exhibited features of dystonia that further interfered with her
use of the right arm. Despite the unremarkable CSF analyses,
clinical suspicion for progressive multifocal leukoencephal-
opathy (PML) remained high, although natalizumab was
redosed once at 3 months to reduce the risk for potential
rebound disease activity.1
Differential diagnosis
The patient’s right upper extremity tremor corresponded with
a new lesion that localized to the left ventral lateral posterior
aspect of the thalamic nuclear complex—the target for the
projections emanating from the right dentate nucleus of the
cerebellum—which then projects to the left precentral gyrus,
thereby providing right cerebellar influence on limb move-
ments in the right arm.
At the time of presentation, the possibility of a new MS de-
myelinating lesion was considered high in the differential di-
agnosis. Demyelinating lesions due to MS are commonly
localized in white matter (especially when using conventional
MRI sequences), but focal lesions in the thalamus are also well
documented.2 Typically, however, new demyelinating symp-
tomatic lesions exhibit enhancement, and the absence of such in
our patient compelled us to broaden the diagnostic differential.
Clinical manifestations of PML in MS are diverse and depend
on the areas of the brain involved. Typically, brain MRI shows
a T2 hyperintense/T1 hypointense lesion(s) with sharp
margins, commonly involving subcortical white matter in-
cluding extension into the U-fibers, although cortical in-
volvement is often reported. Contrast enhancement is
exceptional in HIV-associated PML, yet it is seen in about
40% of MS PML cases.3 Despite high sensitivity (>95%) of
CSF PCR for JCV in PML, JCV has infrequently remained
undetectable in the CSF in cases where PML was confirmed
by brain biopsy.4
Final diagnosis
As a precise diagnosis could not be made from the imaging
and laboratory data, a biopsy of the lesion was performed 5
months after presentation. Histology demonstrated bizarre
astrocytes, abundant CD68-positive macrophages, and nu-
clear changes suggestive of viral cytopathic effects. JCV DNA
was detected at 9,964,282 copies/10 μL of extract confirming
the diagnosis of PML.
Discussion
PML is a known complication of treatment with natalizumab
in patients with MS with a history of previous exposure to
JCV.5 Furthermore, risk of PML in patients who test positive
for serum JCV Abs exponentially increases with a history of
previous immunosuppression (e.g., cyclophosphamide,
mitoxantrone, etc) and longer duration of continuous nata-
lizumab therapy (e.g., >24 months).6 This does not include
pulse steroids for treating relapses. This risk is further strati-
fied by the quantitative index where a JCV Ab index >1.5 in
patients with MS treated with natalizumab at 4-week intervals
is associated with high risk of PML,7 although data suggest
that extended interval dosing confers a lower risk of PML
without compromising efficacy.8–10
Diagnostic confirmation of PML can often represent a for-
midable challenge, particularly given the heterogeneity in
imaging characteristics. The conspicuity of PML lesion mor-
phology in the context of HIV/AIDS can be distinctive from
lesions evolving as a consequence of protracted immuno-
suppression in patients with autoimmune disorders.3 In HIV,
PML lesions are typically hypointense and, on occasion, can
exhibit enhancement, whereas such lesions in the context of
patients with MS treated with natalizumab exhibit enhance-
ment in 30%–40% of cases.3 Together, clinical presentation,
radiologic findings, and presence of CSF JCV PCR DNA play
important roles in PML diagnosis, although tissue biopsy also
has a prominent and necessary role when other assessments
fails to confirm the diagnosis.
Our case report presented herein illustrates that in spite of
highly sensitive CSF assays for JCV DNA, such findings
cannot adequately counter against the diagnosis of PML,
particularly when a clinical syndrome in the setting of an
atypical CNS lesion remains suspicious. In situations such as
this, tissue biopsy is imperative and represents the gold
standard.
Treatment of natalizumab-associated PML is complex. Plas-
mapheresis is an option, but one needs to consider the effect
that the rapid removal of natalizumabmay have in accelerating
the development of the immune reconstitution inflammatory
syndrome (IRIS). This is especially important because the
clinical outcome can be worse with early PML-IRIS compared
with late PML-IRIS.11 Corticosteroids may be used for PML-
IRIS and have demonstrated benefit when used judiciously,
although no randomized control studies are available.
The patient experienced clinical worsening with increased
right sided weakness and dystonic tremor a few weeks after
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the biopsy. Postcontrast MRI performed at this time (27
weeks after symptom onset) showed nodular enhancement in
the right frontal and parietal subcortical white matter, left
frontal periventricular and precentral subcortical white
matter, and in the left dorsolateral pons in the region of the
left superior cerebellar peduncle (figure 3, small arrow heads).
Steroids were not used at this time because she had not tol-
erated them well on earlier administration. Instead, the
Figure 1 Chronological heat map
In this figure, we detail the condition of the patient over time. The longitudinal axis (left to right) depicts the condition of disease, where the smaller amplitude
and lighter color indicates greater stability of MS. Alternately, the expanded amplitude of the colored heat map (above and below the horizontal linear axis
over time) designates increased disease activity (whether on a clinical or paraclinical basis) or complications of the treatment of disease (e.g., PML). Four other
fields of information are added either above or below the heat map and include information about treatments, diagnoses, commentaries adding contextual
perspectives, and results from specific test assessments from each most relevant period of clinical decision-making. Each field is consistently color coded
throughout as defined in the figure legend. IRIS = immune reconstitution inflammatory syndrome; IVIG = IV immunoglobulin; JCV Ab = John Cunningham
Polyomavirus antibody; LFT = liver function test; PML = progressive multifocal leukoencephalopathy.
Figure 2 Evolution of the left thalamic lesion
In (A), an axial T2 fluid-attenuated in-
version recovery (FLAIR) image dem-
onstrates a new hyperintense lesion
localized to the left thalamus (red ar-
rows), with periventricular and juxta-
cortical lesions typical of MS. In (B), an
axial T1 postcontrast scan shows
hypointensity of the left thalamic lesion
without contrast enhancement. In
(C–G), we present axial FLAIR images
performed serially at 3, 7, 11, 16, and 20
weeks, respectively, after the inception
of the right upper extremity tremor.
Over this period, the lesion has slightly
increased in size, and in (F), the lesion
takes on a ring configuration with cen-
tral hypointensity (red arrows). This
lesion failed to exhibit any evidence of
contrast enhancement over the period
of surveillance imaging.
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patient was treated with 0.4 g/kg/d IV immunoglobulin for a
total of 5 days, after which she exhibited further improvement
in her symptoms.
Unfortunately, there are limited data in the literature re-
garding disease-modifying therapy (DMT) options in such
patients who have been diagnosed with natalizumab-
associated PML. However, one small case series suggests
that INF-β and GA, as well as dimethyl fumarate and fingo-
limod, seem to be safe in post-PML patients, although long-
term safety data are lacking.12,13 There are a few case reports
that describe utilization of rituximab in post-PML patients.14
In the case reported herein, there was significant concern that use
of an immunosuppressive DMTmight provoke recrudescence of
PML, thereby compromising neurologic recovery. As such, the
patient was started on immunomodulatory therapy, in spite of its
previous incomplete effectiveness for treating her MS. Specifi-
cally, IFN-β 1b was selected over daily subcutaneous GA because
of presumedmore rapid onset of actionwith IFN therapy and the
patient preference regarding tolerability with fewer injections.
The patient tolerated IFN-β 1b without side effects or ra-
diologic activity for 19 months. However, she then developed
a left parietal lobe T2 hyperintensity that demonstrated in-
complete peripheral Gd-enhancement, most compatible with
an active MS lesion. Repeat MRIs after 2 and 4 months
showed additional new enhancing lesions, although the pre-
viously identified left thalamic lesion and the subcortical white
matter changes extending from the left thalamus to prefrontal
cortex seemed less conspicuous. IFN-β neutralizing anti-
bodies were not detected.
Once clinical stabilization was achieved, attention then shifted
to the intensification of the patient’s MS DMT, with the goal
to use an agent with properties capable of achieving a durable
remission while also conferring a low risk of PML re-
crudescence. For these reasons, once-daily oral teriflunomide
was identified as an acceptable next step in the patient’s
treatment course (figure 1). This agent targets the bio-
synthetic enzyme, dihydro-orotate dehydrogenase, thereby
inhibiting the de novo pyrimidine synthesis pathway (prin-
cipally used by rapidly dividing cells such as T and
B lymphocytes and for virion replication).
To date, our patient has remained clinically and radiologically
stable for more than 2 years after the treatment transition to
teriflunomide. Despite the achievement of this period of re-
mission in our patient’s disease activity, careful and systematic
clinical and paraclinical surveillance investigations will be
imperative. Until evidence-based data sufficient to provide
treatment guidelines become available, the management of
MS after the development and survival of PML must be for-
mulated on a case-by-case basis.
Acknowledgment
The authors thank medical illustrators Mr. Jason Ooi and Dr.
Matthew Parsons for their creation of the chronological heat
map (figure 1).
Study funding
The National Multiple Sclerosis Society Case Conference
Proceedings is a peer review publishing initiative from the
monthly “Diagnostic and Treatment Challenges in MS and
Neuroimmunology Webinars”; sponsored by the National
Multiple Sclerosis Society Fellowship Training Program.
Disclosure
N. Anadani: clinical fellowship funded by National MS Soci-
ety. M. Hyland: research support from Biogen, PCORI. R.A.
Figure 3 Interval neuroradiographic progression
In (A), we present axial fluid-attenu-
ated inversion recovery images re-
vealing disseminated lesions
characteristic for inflammatory de-
myelination in the periventribular
zones, in the centrum semiovale, in the
corona radiata, and in the cortex and
juxtacortical zones, in addition to the
previously identified left thalamic le-
sion, here exhibiting a ring configura-
tion with central hypointensity (red
arrow). In (B), we present axial T1
postcontrast images showing various
nodular enhancing lesions in left dor-
solateral pons and bilateral frontal
lobes and patchy punctate enhance-
ments in left frontal and parietal white
matter (red arrows).
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